Rotavirus Vaccine Take in Infants Is Associated With Secretor Status

• Published in: The Journal of infectious diseases Vol. 219; no. 5; pp. 746 - 749
• Main Authors: Armah, George E, Cortese, Margaret M, Dennis, Francis E, Yu, Ying, Morrow, Ardythe L, McNeal, Monica M, Lewis, Kristen D C, Awuni, Denis A, Armachie, Joseph, Parashar, Umesh D
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 15.02.2019
• Subjects: Antigens; Enterocytes; Genotypes; Immunoglobulin A; Infants; Lewis antigen; Rotavirus; Saliva; Seroconversion; Vaccines; Viruses; secretor; vaccine; Lewis antigen; rotavirus; FUT2
• ISSN: 0022-1899; 1537-6613
• DOI: 10.1093/infdis/jiy573

Abstract Rotaviruses bind to enterocytes in a genotype-specific manner via histo-blood group antigens (HBGAs), which are also detectable in saliva. We evaluated antirotavirus immunoglobulin A seroconversion (‘vaccine take”) among 166 Ghanaian infants after 2–3 doses of G1P[8] rotavirus vaccine during a vaccine trial, by HBGA status from saliva collected at age 4.1 years. Only secretor status was associated with seroconversion: 41% seroconversion for secretors vs 13% for nonsecretors; relative risk, 3.2 (95% confidence interval, 1.2–8.1; P = .016). Neither Lewis antigen nor salivary antigen blood type was associated with seroconversion. Likelihood of “take” for any particular rotavirus vaccine may differ across populations based on HBGAs. Infants who are nonsecretors were about one-third as likely to have a serum antibody response after receiving oral G1P[8] rotavirus vaccine than secretors. Likelihood of “take” for any particular rotavirus vaccine may differ across populations based on histo-blood group antigens.